Search Results
Dr Darren McGuire Debates SGLT2 Inhibitors and GLP-1 Receptor Agonists as CVD Prime Time Prevention
GLP-1 ( Liraglutide )&Cardiovascular Disease in Patients with Type 2 Diabetes,Organized by ICC, 2020
PG Debate on SGLT2 inhibitors Dr Prithvi and Dr Amit
Pfizer symposium - How is the Science of CV Risk Reduction Evolving?
HEALTHY BITE | Relative Risk VS Absolute Risk... An Important Public Health Message
“Treatment of type 2 diabetes: A sound approach based upon its Pathophysiology” by Ralph DeFronzo,MD
